6th Annual Recombinant Antibodies 2013

Topics

• Immune effector functions through targeted Fc region engineering
• The potency of IgG molecules for ADCC, ADCP and CDC applications
• Pharmacokinetic half-life and exposure
• In vivo circulation time with conjugated immunoglobulins
• Antigen-binding domains
• Silico tools during early-phase research
• Technologies for selecting antibody attributes
• Decreased immunogenicity, cross-reactivity and in vivo toxicity
• Inflammatory disease, and solid and liquid cancer targets
• Site-specific drug loading for bispecific antibodies
• Angiogenic signalling pathways and disrupt the tumour microenvironment

Who should Attend

Executives and managers of Recombinant DNA/molecular biotechnology, Antibody design, production and development, Biotherapeutics, Protein/biochemical engineering, Bio-analytical and protein-analytical R&D, and analytical chemistry, Assay and cell display technologies, Preclinical/clinical research and development, Process development, CNS, autoimmune and inflammatory disease research, Oncology, Immunobiology and immunogenicity testing, Arthritis, colorectal/breast/lymphoma/prostate/lung cancer R&D, Business and alliance development, Pharmacovigilance, Biosimilars, Marketing and licensing, Regulatory affairs, pharmaceutical and patent law, Contract manufacturing and research organisations, Pharmaceutical and patent law.